dr. mesa on ruxolitinib in myelofibrosis
Published 11 years ago • 199 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
1:36
dr. mesa on the mechanism of action of ruxolitinib in cml
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:36
dr. mesa gives an overview of upcoming trials in myelofibrosis
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:26
mesa advises community oncologists on jak inhibitors for intermediate-risk myelofibrosis
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:19
dr. mesa on ruxolitinib in chronic myeloid leukemia
-
1:40
considering fedratinib or ruxolitinib in the frontline setting for treatment of myelofibrosis
-
4:45
myelofibrosis: long-term survival data and ruxolitinib use
-
3:42
treatment considerations in myelofibrosis
-
5:31
case 1: ruxolitinib treatment for myelofibrosis
-
1:52
dr. john mascarenhas on the comfort-i/ii studies for ruxolitinib in myelofibrosis
-
5:33
ruben mesa, md: momelotinib non-inferior to ruxolitinib in myelofibrosis